Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Pусский | Português | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2010DISEASENETWORKREGISTRYPREDICTPROJECTSLOGIN
  
 
  
News of European HD Network -
--->News
[+]The Project
[-]Locations
--->[+]Austria
--->[+]Belgium
--->[+]Czech Republic
--->[+]Denmark
--->[+]Finland
--->[+]France
--->[+]Germany
--->[+]Italy
--->[+]Netherlands
--->[+]Norway
--->[+]Poland
--->[+]Portugal
--->[+]Russia
--->[-]Spain
--->Coordination
--->HD Associations
--->Alicante-Alcoy
--->Badajoz
--->Barcelona - Bellvitge
--->Barcelona - Clinic i Provincia...
--->Barcelona - Mutua de Terra...
--->Barcelona - Santa Creu i Sa...
--->Barcelona - Merced
--->Burgos
--->Granada
--->Fuenlabrada
--->Madrid - Clínico
--->Madrid - FJD
--->Madrid - RyC
--->Murcia
--->Oviedo
--->Palma de Mallorca
--->Pamplona
--->Sevilla
--->Sevilla-HUVRocio
--->Valencia
--->_Santiago
--->[+]Sweden
--->[+]Switzerland
--->[+]U.K.
[-]Working Groups
--->[+]Advanced HD
--->[+]Behavioural Phenotype
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brain and Tissue Banking
--->[+]Cognitive Phenotype
--->[+]Environmental Modifiers
--->[+]Functional Ability
--->[+]Genetic Testing
--->[+]Genetic Modifiers
--->[+]Health Economics
--->[+]Imaging
--->[+]Juvenile HD
--->[+]Motor Phenotype
--->[+]Neuroprotective Therapy
--->[+]Physiotherapy
--->[+]Quality of Life
--->[+]Standard of Care
--->[+]Surgical Approaches
--->[-]Symptomatic Research
--->[+]Dates
--->[+]Meetings
--->[+]Youth
[-]Events
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[+]Communication
--->Job Offers
HORIZON A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dimebon in Patients with Mild-To-Moderate Huntington Disease

Horizon trial website

Under the direction of Karl Kieburtz, MD, MPH, Principal Investigator (University of Rochester), and Bernhard Landwehrmeyer, MD, co-Principal Investigator (University of Ulm), the Huntington Study Group (HSG), and the European Huntington’s Disease Network (EHDN) are conducting a global collaborative multi-center, randomized, double-blind, placebo-controlled study of Dimebon in individuals with mild-to-moderate Huntington disease (HD). The purpose of the study is to assess the safety and efficacy of Dimebon 60 mg per day, when taken over a period of 6 months. Efficacy is determined by exploring whether or not there is an effect on cognitive (thinking) abilities and overall functioning in people with HD. The study will also evaluate other HD symptoms including behavioral and motor (movement) symptoms. Approximately 50 research centers across North America, Europe, Australia, and New Zealand will enroll approximately 350 individuals. Dimebon is an experimental drug. Research has shown that Dimebon might be effective in preventing the death of brain cells in animals and improving thinking and memory in Alzheimer disease. Results of a HD study in the United States and United Kingdom showed that Dimebon 60mg per day was safe and well tolerated and suggested that Dimebon may improve cognition (thinking abilities) in individuals with HD. This study is being sponsored by Medivation, Inc in collaboration with Pfizer, Inc.

For more information: please call Jenny Naji at the European Huntington’s Disease Network on +44 7791 985313 or email najijj@cf.ac.uk[back]
about us privacy statement disclaimer terms of use